Gerson D Hernandez
- Senior Director, Clinical Trials - Center for Innovation in Brain Science
- Assistant Research Professor, Neurology
Biography
Dr. Hernandez is a clinical researcher trained as both a physician and a public health professional. As the Senior Director of Clinical Trials at the Center for Innovation in Brain Science (CIBS), he leads the design, planning, and execution of patient-centered clinical trials focused on the development of therapies for age-related neurodegenerative diseases. His research has spanned women’s health and now focuses on the aging brain and its heightened risk for Alzheimer’s disease, particularly in women.
Dr. Hernandez has served in key leadership roles, including as multi-PI and Co-investigator, on NIH/NIA and foundation funded clinical trials in Alzheimer’s disease (NCT02221622, NCT03748303, NCT04838301), Parkinson’s disease (NCT06263010) and female brain health (NCT01723917, NCT05664477, NCT06186531). He currently serves as co-Leader for the Research Education Component Core of the Arizona Alzheimer's Disease Research Center (ADRC).
Degrees
- MPH Medicine
- University of Southern California, Los Angeles, California, United States
- Postdoc Maternal-Fetal Medicine
- University of Southern California, Los Angeles, California, United States
- M.D. Medicine
- Universidad Francisco Marroquin, Guatemala City, Guatemala
Awards
- AZ ADRC-REC Fellowship
- Arizona Alzheimer’s Disease Research Center (AZ-ADRC), Fall 2021
Interests
Research
Alzheimer's disease and other neurodegenerative diseases / Brain health / Women's health
Courses
No activities entered.
Scholarly Contributions
Journals/Publications
- Brinton, R. D., Hernandez, G. D., Raikes, A. C., Matthews, D. C., Lukic, A. S., Law, M., Shi, Y., & Schneider, L. S. (2022). Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 8(1). doi:10.1002/trc2.12258
- Chilton, F., Killgore, W. D., Mullins, V. A., Hernandez, G. D., Raikes, A. C., Wang, Y., Lopez, C. M., & Brinton, R. D. (2022). In‐season docosahexaenoic acid supplementation does not prevent white matter damage during a single American football season: Implications for neurodegeneration prevention. Alzheimer's & Dementia, 18(S11). doi:10.1002/alz.065751
- Hernandez, G., Lopez, C., Mack, W., Pawluczyk, S., Matthews, D., Shi, Y., Law, M., Rogawski, M., Schneider, L., & Brinton, R. D. (2022). Allopregnanolone as a Regenerative Therapeutic for Early Alzheimer’s Disease: Phase 1b/2a Clinical Trial Outcomes (P6-3.001). Neurology, 98(18_supplement). doi:10.1212/wnl.98.18_supplement.1781
- Brinton, R. D., Rodgers, K. E., Hernandez, G. D., Solinsky, C. M., Mack, W. J., Kono, N., Wu, C., Mollo, A. R., Lopez, C. M., Pawluczyk, S., Bauer, G., Matthews, D., Shi, Y., Law, M., Rogawski, M. A., & Schneider, L. S. (2020). Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 6(1). doi:10.1002/trc2.12107
- Hernandez, G. D., Solinsky, C. M., Mack, W. J., Kono, N., Rodgers, K. E., Wu, C. Y., Mollo, A. R., Lopez, C. M., Pawluczyk, S., Bauer, G., Matthews, D., Shi, Y., Law, M., Rogawski, M. A., Schneider, L. S., & Brinton, R. D. (2020). Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. Alzheimer's & dementia (New York, N. Y.), 6(1), e12107.More infoAllopregnanolone is an endogenous neurosteroid with the potential to be a novel regenerative therapeutic for Alzheimer's disease (AD). Foundations of mechanistic understanding and well-established preclinical safety efficacy make it a viable candidate.
- Rodgers, K. E., Hernandez, G. D., Lopez, C. M., Wang, Y., Schneider, L., & Brinton, R. D. (2020). Pharmacokinetics and safety profile of intramuscular administration of allopregnanolone in patients with Alzheimer’s disease: Human/Human trials: Other. Alzheimer's & Dementia, 16(S9). doi:10.1002/alz.046223
- Brinton, R. D., Hernandez, G. D., Wang, Y., Solinsky, C. M., & Schneider, L. S. (2019). P3-032: COMBINING SEX, APOE GENOTYPE, AND MITOCHONDRIAL GENETIC VARIANCE AS PREDICTIVE RESPONDER IDENTIFIER TO REGENERATIVE THERAPEUTIC ALLOPREGNANOLONE FOR ALZHEIMER'S DISEASE. Alzheimer's & Dementia, 15(7S_Part_4), P938-P938. doi:10.1016/j.jalz.2019.06.3058
Proceedings Publications
- Hernandez, G. D., Brinton, R. D., Schneider, L. S., Cutter, G. R., Matthews, D. C., Rodgers, K. E., Raikes, A. C., & Lopez, C. M. (2022). Allopregnanolone as a Regenerative Therapeutic for Alzheimer’s Disease: Phase 2 proof‐of‐concept clinical trial using hippocampal volume as a surrogate endpoint. In Alzheimers & Dementia, 18.
Poster Presentations
- Raikes, A., Hernandez, G., Lopez, C. M., Schneider, L. S., & Brinton, R. (2024, October). Allopregnanolone preserves white matter structrue independent of APOE genotype in early Alzheimer's disease. 17th Clinical Trials in Alzheimer's Disease (CTAD 2024). Madrid, Spain.
